Muscle Ultrasound Can Detect Insulin Resistance
By Elana Gotkine HealthDay Reporter
MONDAY, June 30, 2025 -- Muscle ultrasound can detect insulin resistance and lower muscle mass, according to a study published online June 12 in the Journal of Ultrasound Medicine.
Steven B. Soliman, D.O., from the University of Michigan in Ann Arbor, and colleagues examined the potential use of noninvasive muscle ultrasound for detecting early-developing insulin resistance and lower muscle mass in a study involving 20 subjects with obesity, without type 2 diabetes or prediabetes, and five healthy lean controls. Participants underwent ultrasound of their deltoid and vastus lateralis muscles. Three hundred ultrasound images were analyzed independently by two trained research assistants, measuring muscle echo intensity (MEI). Peripheral insulin sensitivity was assessed in the obesity cohort; body composition was also examined and sarcopenia indices were calculated.
The researchers found that vastus lateralis and deltoid MEI were significantly higher in the obesity cohort, with increased MEI effectively identifying insulin resistance and impaired insulin sensitivity. Excellent interobserver agreement was seen for both the deltoid and vastus lateralis muscles (95 percent confidence interval of intraclass correlation coefficient, 0.96 to 0.997 and 0.986 to 0.999, respectively). There was a negative correlation seen for MEI with muscle mass, as indicated by sarcopenia indices, and no positive correlation seen with body mass index or body weight.
"A medical assistant or clinician with little to no training could easily use this device on a patient's upper arm or thigh, as routinely as checking weight or blood pressure, and potentially flag patients as 'high risk' or 'low risk' for further testing," Soliman said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk
WEDNESDAY, July 23, 2025 -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with...
Endocrine Society, July 12-15
The annual meeting of the Endocrine Society (ENDO 2025) was held from July 12 to 15 in San Francisco, attracting more than 7,000 participants, including clinicians, academicians...
Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity
TUESDAY, July 22, 2025 -- For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.